SCHEMBL22645552

SCHEMBL22645552

CCCNC(=O)/C(=C/c1ccccc1)NC(=O)/C=C/c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.53
NLRP3 Q96P20 1/20 0.53
KMT2A Q03164 5/20 0.53
MEN1 O00255 4/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
ALDH1A1 P00352 3/20 0.53
NPSR1 Q6W5P4 1/20 0.53
PLAAT3 P53816 1/20 0.51
PLAAT5 Q96KN8 1/20 0.51
PLAAT2 Q9NWW9 1/20 0.51
PLAAT4 Q9UL19 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.49
EGFR P00533 2/20 0.49
LMNA P02545 2/20 0.49
MMP1 P03956 1/20 0.49
MMP2 P08253 1/20 0.49
MMP9 P14780 1/20 0.49
HDAC3 O15379 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22645341 0.93 ALDH1A1 (0.59) MAPTKMT2AALDH1A1NPSR1PLAAT3
SCHEMBL22645560 0.90 KCNA3 (0.51) MAPTNLRP3KMT2AMEN1CYP1A2
SCHEMBL22645524 0.89 ALDH1A1 (0.54) KMT2AMEN1ALDH1A1NPSR1SMN1; SMN2
SCHEMBL22645393 0.88 ALDH1A1 (0.53) KMT2AMEN1ALDH1A1NPSR1SMN1; SMN2
SCHEMBL22645390 0.88 ALDH1A1 (0.53) KMT2AMEN1ALDH1A1NPSR1SMN1; SMN2
SCHEMBL22662495 0.88 ALDH1A1 (0.53) KMT2AMEN1ALDH1A1NPSR1SMN1; SMN2
SCHEMBL22645349 0.88 MAPT (0.55) MAPTNLRP3KMT2AMEN1CYP1A2
SCHEMBL22645443 0.86 KMT2A (0.57) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL22645382 0.86 ALDH1A1 (0.51) MAPTKMT2AMEN1ALDH1A1NPSR1
SCHEMBL22645300 0.85 EGFR (0.64) MAPTKMT2AALDH1A1NPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11312694-B2 Method for making propenamide compound KING ABDULAZIZ UNIVERSITY (SA) 2022-04-26 US disclosed
US-11312694-B2 Method for making propenamide compound KING ABDULAZIZ UNIVERSITY (SA) 2022-04-26 US disclosed
US-20220033368-A1 METHOD FOR MAKING PROPENAMIDE COMPOUND KING ABDULAZIZ UNIVERSITY (SA) 2022-02-03 US disclosed
US-20220033368-A1 METHOD FOR MAKING PROPENAMIDE COMPOUND KING ABDULAZIZ UNIVERSITY (SA) 2022-02-03 US disclosed
US-20220009896-A1 METHOD OF TREATING COLORECTAL CANCER KING ABDULAZIZ UNIVERSITY (SA) 2022-01-13 US disclosed
US-20220009896-A1 METHOD OF TREATING COLORECTAL CANCER KING ABDULAZIZ UNIVERSITY (SA) 2022-01-13 US disclosed
US-11214556-B1 Method of treating colorectal cancer KING ABDULAZIZ UNIVERSITY (SA) 2022-01-04 US disclosed
US-11214556-B1 Method of treating colorectal cancer KING ABDULAZIZ UNIVERSITY (SA) 2022-01-04 US disclosed
US-11155528-B2 Bis-propenamide compounds and methods of treating cancer KING ABDULAZIZ UNIVERSITY (SA) 2021-10-26 US disclosed
US-11155528-B2 Bis-propenamide compounds and methods of treating cancer KING ABDULAZIZ UNIVERSITY (SA) 2021-10-26 US disclosed
US-20210122721-A1 BIS-PROPENAMIDE COMPOUNDS AND METHODS OF TREATING CANCER KING ABDULAZIZ UNIVERSITY (SA) 2021-04-29 US disclosed
US-20210122721-A1 BIS-PROPENAMIDE COMPOUNDS AND METHODS OF TREATING CANCER KING ABDULAZIZ UNIVERSITY (SA) 2021-04-29 US disclosed
US-10836736-B1 Pharmaceutical composition with cytotoxic activity on colorectal cancer cells KING ABDULAZIZ UNIVERSITY (SA) 2020-11-17 US disclosed
US-10836736-B1 Pharmaceutical composition with cytotoxic activity on colorectal cancer cells KING ABDULAZIZ UNIVERSITY (SA) 2020-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10836736-B1 Pharmaceutical composition with cytotoxic activity on colorectal cancer cells APC, DCK, ABCB1 MAPT 4583/4885NLRP3 4334/4885KMT2A 3367/4885
US-20210122721-A1 BIS-PROPENAMIDE COMPOUNDS AND METHODS OF TREATING CANCER APC, CCNE1, CCNI MAPT 3640/4885NLRP3 4789/4885KMT2A 2626/4885
US-20220009896-A1 METHOD OF TREATING COLORECTAL CANCER APC, SLC10A2, FOLR1 MAPT 4626/4885NLRP3 4512/4885KMT2A 2411/4885
US-11312694-B2 Method for making propenamide compound APC, CYP2C19, PKD1 MAPT 3739/4885NLRP3 4526/4885KMT2A 2433/4885
US-20220033368-A1 METHOD FOR MAKING PROPENAMIDE COMPOUND APC, CYP2C19, PKD1 MAPT 3739/4885NLRP3 4526/4885KMT2A 2433/4885
US-11155528-B2 Bis-propenamide compounds and methods of treating cancer APC, CCNE1, CCNI MAPT 3640/4885NLRP3 4789/4885KMT2A 2626/4885
US-11214556-B1 Method of treating colorectal cancer APC, SLC10A2, FOLR1 MAPT 4626/4885NLRP3 4512/4885KMT2A 2411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.